{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T05:50:11Z","timestamp":1775195411783,"version":"3.50.1"},"reference-count":21,"publisher":"Pharmaceutical Society of Japan","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2021,4,1]]},"DOI":"10.1248\/bpb.b20-01028","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T22:07:58Z","timestamp":1617228478000},"page":"593-598","source":"Crossref","is-referenced-by-count":6,"title":["Construction of a Risk Prediction Model of Extended Release Oxycodone Tablet-Induced Nausea and Clarification of Predictive Factors"],"prefix":"10.1248","volume":"44","author":[{"given":"Masayoshi","family":"Kumai","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"},{"name":"Cancer Center Palliative Care Team, Hokkaido University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shungo","family":"Imai","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"},{"name":"Cancer Center Palliative Care Team, Hokkaido University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Koyanagi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"},{"name":"Cancer Center Palliative Care Team, Hokkaido University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenkichi","family":"Tsuruga","sequence":"additional","affiliation":[{"name":"Cancer Center Palliative Care Team, Hokkaido University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiro","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, Faculty of Pharmaceutical Sciences, Hokkaido University of Science"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"},{"name":"Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Laugsand EA, Kaasa S, Klepstad P. Management of opioid-induced nausea and vomiting in cancer patients: systematic review and evidence-based recommendations. <i>Palliat. Med.<\/i>, <b>25<\/b>, 442\u2013453 (2011)."},{"key":"2","unstructured":"2) <i>Clinical Guidelines for Cancer Pain Management, Third Edition<\/i>. KANEHARA &amp; Co., Ltd., Tokyo, Japan (2020)."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Ishihara M, Ikesue H, Matsunaga H, Suemaru K, Kitaichi K, Suetsugu K, Oishi R, Sendo T, Araki H, Itoh Y. A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. <i>Clin. J. Pain<\/i>, <b>28<\/b>, 373\u2013381 (2012).","DOI":"10.1097\/AJP.0b013e318237d626"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Ariyoshi K, Kitahara T, Ryu E, Takada M, Munakata C, Nose S. Clinical risk factors associated with nausea and vomiting in patients receiving extended-release oxycodone. <i>Japanese J. Pharm. Heal. Care Sci.<\/i>, <b>39<\/b>, 280\u2013288 (2013).","DOI":"10.5649\/jjphcs.39.134"},{"key":"5","unstructured":"5) Kanbayashi Y, Hosokawa T. Predictive factors for nausea or vomiting in patients with cancer who receive oral oxycodone for the first time: is prophylactic medication for prevention of opioid-induced nausea or vomiting necessary? <i>J. Palliat. Med.<\/i>, <b>17<\/b>, 683\u2013687 (2014)."},{"key":"6","unstructured":"6) Imai S, Yamada T, Kasashi K, Kobayashi M, Iseki K. Usefulness of a decision tree model for the analysis of adverse drug reactions: Evaluation of a risk prediction model of vancomycin-associated nephrotoxicity constructed using a data mining procedure. <i>J. Eval. Clin. Pract.<\/i>, <b>23<\/b>, 1240\u20131246 (2017)."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Imai S, Yamada T, Kobayashi M, Kasashi K, Iseki K. Analysis of risk factors for ganciclovir-induced neutropenia using a data mining procedure. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)<\/i>, <b>43<\/b>, 552\u2013562 (2017).","DOI":"10.5649\/jjphcs.43.552"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Akoglu H. User\u2019s guide to correlation coefficients. Turk. J. Emerg. Med., 18, 91\u201393 (2018).","DOI":"10.1016\/j.tjem.2018.08.001"},{"key":"9","unstructured":"9) Kume H, Masayuki M, Hiroshi K, Ai M, Hiroaki T, Sugishita M, Adachi Y, Ando Y, Yamada K. Efficacy of prophylactic anti-emetics for prevention of oxycodone-induced nausea and vomiting. <i>Jpn. J. Pharm. Palliat. Care Sci.<\/i>, <b>9<\/b>, 75\u201380 (2016)."},{"key":"10","unstructured":"10) Hashizume J, Ryu E, Munakata C, Nose S, Kakugawa K, Miyanaga K, Kishikawa R, Ishii K, Nakamura T, Kitahara T, Sasaki H, Muro T. Current survey and efficiency evaluation of the preventive antiemetics for oxycodone-induced nausea and vomiting during aggressive cancer therapy. <i>Jpn. J. Pharm. Palliat. Care Sci.<\/i>, <b>11<\/b>, 119\u2013125 (2018)."},{"key":"11","unstructured":"11) Zuniga JR, Papas AS, Daniels SE, Patrick K, Muse DD, Oreadi D, Giannakopoulos HE, Granquist EJ, Levin LM, Chou JC, Maibach H, Schachtel BP. Prevention of opioid-induced nausea and vomiting during treatment of moderate to severe acute pain: a randomized placebo-controlled trial comparing CL-108 (hydrocodone 7.5\u2009mg\/acetaminophen 325\u2009mg\/rapid-release, low-dose promethazine 12.5\u2009mg) with Conventional Hydrocodone 7.5\u2009mg\/Acetaminophen 325\u2009mg. <i>Pain Med.<\/i>, <b>20<\/b>, 2528\u20132538 (2019)."},{"key":"12","unstructured":"12) Merck &amp; Co. Inc., Kenilworth, NJ, U.S.A. \u201cNausea and vomiting\u201d.: \u2039https:\/\/www.msdmanuals.com\/professional\/gastrointestinal-disorders\/symptoms-of-gastrointestinal-disorders\/nausea-and-vomiting?query=nauseavomiting#\u203a, accessed 7 January, 2021."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Yamada M, Matsumura C, Jimaru Y, Ueno R, Torii S, Takahashi K, Yano Y. Effect of chemotherapy and predictive factors for nausea or vomiting in patients with cancer receiving opioid analgesics for the first time. <i>Palliat. Care Res.<\/i>, <b>15<\/b>, 213\u2013220 (2020).","DOI":"10.2512\/jspm.15.213"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Apfel CC, Heidrich FM, Jukar-Rao S, Jalota L, Hornuss C, Whelan RP, Zhang K, Cakmakkaya OS. Evidence-based analysis of risk factors for postoperative nausea and vomiting. <i>Br. J. Anaesth.<\/i>, <b>109<\/b>, 742\u2013753 (2012).","DOI":"10.1093\/bja\/aes276"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Warr D. Prognostic factors for chemotherapy induced nausea and vomiting. <i>Eur. J. Pharmacol.<\/i>, <b>722<\/b>, 192\u2013196 (2014).","DOI":"10.1016\/j.ejphar.2013.10.015"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Kurdi MS, Ramaswamy AH. Does the phase of the menstrual cycle really matter to anaesthesia? <i>Indian J. Anaesth.<\/i>, <b>62<\/b>, 330\u2013336 (2018).","DOI":"10.4103\/ija.IJA_139_18"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Yoest KE, Cummings JA, Becker JB. Estradiol, dopamine and motivation. <i>Cent. Nerv. Syst. Agents Med. Chem.<\/i>, <b>14<\/b>, 83\u201389 (2015).","DOI":"10.2174\/1871524914666141226103135"},{"key":"18","unstructured":"18) Tamada T, Iwasaki H. Age at natural menopause in Japanese women. <i>Nihon Sanka Fujinka Gakkai Zasshi<\/i>, <b>47<\/b>, 947\u2013952 (1995)."},{"key":"19","unstructured":"19) <i>Clinacal Guidlines for Gastrointestinal Symptoms in Cancer Patients, 2nd Edition<\/i>. KANEHARA &amp; Co., Ltd., Tokyo, Japan (2017)."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Beattie WS, Lindblad T, Buckley N, Forrest JB. Menstruation increases the risk of nausea and vomiting after laparoscopy. A prospective randomized study. <i>Anesthesiology<\/i>, <b>78<\/b>, 272\u2013276 (1993).","DOI":"10.1097\/00000542-199302000-00010"},{"key":"21","unstructured":"21) National Comprehensive Cancer Network. \u201cAdult cancer pain version 1.2020.\u201d: \u2039https:\/\/www.nccn.org\/default.aspx\u203a, accessed 20 November, 2020."}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/4\/44_b20-01028\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T03:30:03Z","timestamp":1617420603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/4\/44_b20-01028\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b20-01028","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]}}}